Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18939382 | POST-OPERATIVE INDWELLING URINARY CATHETER SUITABLE FOR MALES | November 2024 | January 2025 | Allow | 3 | 0 | 0 | No | No |
| 18926513 | Methods And Systems For High-Throughput Blood Component Collection | October 2024 | February 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 18925370 | Needle Dislodgement Detection Systems and Methods | October 2024 | April 2025 | Allow | 6 | 0 | 0 | No | No |
| 18666279 | Fluid transfer device | May 2024 | September 2024 | Allow | 4 | 0 | 1 | No | No |
| 18642779 | METHOD AND APPARATUS FOR CATHETER-BASED EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) | April 2024 | October 2024 | Allow | 6 | 1 | 0 | No | No |
| 18592373 | METHOD AND APPARATUS FOR CATHETER-BASED EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) | February 2024 | March 2025 | Allow | 12 | 2 | 1 | No | No |
| 18531750 | MEMBRANE OXYGENATORS | December 2023 | April 2024 | Allow | 5 | 1 | 0 | No | No |
| 18484398 | METHOD AND APPARATUS FOR CATHETER-BASED EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) | October 2023 | November 2023 | Allow | 2 | 0 | 0 | No | No |
| 18356133 | INTRAOCULAR DRUG DELIVERY SYSTEMS AND METHODS OF USE | July 2023 | August 2024 | Allow | 13 | 1 | 1 | Yes | No |
| 18261673 | Device for Shunting Blood Between the Arterial and Venous Systems | July 2023 | April 2024 | Allow | 9 | 1 | 0 | No | No |
| 18320108 | SHUNT FOR REDISTRIBUTING ATRIAL BLOOD VOLUME | May 2023 | August 2024 | Allow | 15 | 2 | 1 | Yes | No |
| 18103008 | Methods And Systems For High-Throughput Blood Component Collection | January 2023 | November 2023 | Allow | 9 | 1 | 0 | No | No |
| 18103111 | Methods And Systems For High-Throughput Blood Component Collection | January 2023 | January 2024 | Allow | 11 | 2 | 0 | No | No |
| 18069025 | Left Atrial Appendage Stasis Reduction | December 2022 | September 2023 | Allow | 9 | 1 | 0 | Yes | No |
| 17823047 | SHUNT FOR REDISTRIBUTING ATRIAL BLOOD VOLUME | August 2022 | October 2023 | Allow | 14 | 2 | 0 | Yes | No |
| 17872377 | DEVICE FOR REMOVING BY SUCTION A BODILY FLUID, PRIMARILY NASAL FLUID | July 2022 | October 2024 | Allow | 27 | 1 | 0 | No | No |
| 17863896 | DUAL LUMEN CANNULA WITH EXPANDABLE LUMEN | July 2022 | July 2025 | Allow | 36 | 1 | 0 | No | No |
| 17851480 | POINT OF INJURY DEVICE TO STABILIZE INTRACRANIAL PRESSURE AND METHOD OF STABILIZATION | June 2022 | April 2025 | Allow | 34 | 1 | 0 | No | No |
| 17749454 | METHODS AND SYSTEMS FOR ESTABLISHING RETROGRADE CAROTID ARTERIAL BLOOD FLOW | May 2022 | January 2025 | Allow | 32 | 1 | 0 | No | No |
| 17743655 | Perfusion System with Heat Exchanger | May 2022 | July 2023 | Allow | 14 | 2 | 1 | Yes | No |
| 17739723 | APPARATUS FOR MINIMALLY-INVASIVE PREVENTION AND TREATMENT OF HYDROCEPHALUS AND METHOD FOR USE OF SAME | May 2022 | April 2025 | Allow | 35 | 1 | 0 | No | No |
| 17662413 | Left Atrial Appendage Stasis Reduction | May 2022 | October 2022 | Allow | 6 | 1 | 0 | Yes | No |
| 17734675 | SYSTEMS AND METHODS FOR MEASURING VOLUME OF POTENTIAL SLEEVE IN A SLEEVE GASTRECTOMY | May 2022 | February 2025 | Allow | 34 | 1 | 0 | No | No |
| 17656521 | ASYMMETRIC SHUNT FOR REDISTRIBUTING ATRIAL BLOOD VOLUME | March 2022 | February 2025 | Allow | 34 | 1 | 0 | No | No |
| 17523811 | DUAL LUMEN CANNULA AND METHOD OF USE | November 2021 | September 2022 | Allow | 10 | 1 | 1 | Yes | No |
| 17510680 | Apparatus for Minimally-Invasive Prevention and Treatment of Hydrocephalus and Method for Use of Same | October 2021 | January 2022 | Allow | 2 | 1 | 0 | No | No |
| 17501615 | REDUCED-PRESSURE, MULTI-ORIENTATION, LIQUID-COLLECTION CANISTER | October 2021 | July 2024 | Allow | 33 | 1 | 0 | No | No |
| 17497371 | OXYGENATOR | October 2021 | December 2024 | Allow | 38 | 1 | 0 | No | No |
| 17470371 | System and Method for Facilitating Extracorporeal Inactivation of Pathogens of Blood Products | September 2021 | April 2022 | Allow | 7 | 1 | 0 | No | No |
| 17464523 | Systems and Methods for Treating Blood | September 2021 | November 2024 | Allow | 38 | 1 | 0 | No | No |
| 17408159 | COMPRESSIBLE WOUND FILLERS AND SYSTEMS AND METHODS OF USE IN TREATING WOUNDS WITH NEGATIVE PRESSURE | August 2021 | June 2025 | Allow | 46 | 1 | 1 | No | No |
| 17407999 | IMPLANTABLE INTRACRANIAL PULSE PRESSURE MODULATOR AND SYSTEM AND METHOD FOR USE OF SAME | August 2021 | March 2022 | Allow | 7 | 1 | 0 | Yes | No |
| 17404661 | INTRAVENOUS FLUID BAG WITH AN INTEGRATED VALVE HAVING A SEAL WITH A COMPRESSED STATE THAT PERMITS FLUID FLOW INTO THE BAG AND A RELAXED STATE PREVENTING FLUID FLOW | August 2021 | April 2025 | Allow | 44 | 1 | 0 | No | No |
| 17403178 | ABSORBENT NEGATIVE PRESSURE WOUND THERAPY DRESSING | August 2021 | June 2025 | Allow | 46 | 2 | 0 | No | No |
| 17428654 | INTEGRATED EXTRACORPOREAL OXYGENATION AND CO2 REMOVAL WITH VENTILATION SYSTEM | August 2021 | January 2022 | Allow | 5 | 0 | 0 | No | No |
| 17394182 | Fluid Control and Bypass Features for an Apheresis System | August 2021 | May 2025 | Allow | 45 | 2 | 0 | No | No |
| 17392991 | Self-Loading Fluid Line Loop Arrangement for Centrifuge System | August 2021 | April 2025 | Allow | 44 | 2 | 0 | No | No |
| 17392804 | Methods and Systems for High-Throughput Blood Component Collection | August 2021 | June 2025 | Allow | 46 | 2 | 0 | No | No |
| 17393116 | Filler for an Apheresis System | August 2021 | April 2025 | Allow | 44 | 2 | 0 | No | No |
| 17392482 | Cannula and Balloon System for Extracorporeal Membrane Oxygenation | August 2021 | September 2022 | Abandon | 13 | 2 | 1 | Yes | No |
| 17383091 | DETECTION OF A DISRUPTION OF A FLUID CONNECTION BETWEEN TWO FLUID CONTAINING SYSTEMS | July 2021 | July 2024 | Allow | 36 | 0 | 0 | No | No |
| 17424840 | Left Atrial Appendage Stasis Reduction | July 2021 | April 2022 | Allow | 9 | 1 | 0 | Yes | No |
| 17365568 | IMPLANTABLE FLUID CONDUIT SYSTEM | July 2021 | July 2024 | Allow | 36 | 1 | 0 | No | No |
| 17363274 | ANTISEPTIC VIAL WITH REMOVABLE CAP | June 2021 | January 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17418090 | APPARATUS FOR EXTRACORPOREAL BLOOD TREATMENT | June 2021 | June 2024 | Allow | 36 | 1 | 0 | No | No |
| 17345502 | METHODS AND SYSTEMS FOR ESTABLISHING RETROGRADE CAROTID ARTERIAL BLOOD FLOW | June 2021 | September 2024 | Allow | 39 | 1 | 0 | No | No |
| 17342279 | MULTIPURPOSE WEARABLE ENDOVASCULAR APPARATUS | June 2021 | March 2022 | Allow | 9 | 2 | 0 | No | No |
| 17338209 | MODULAR VIAL ADAPTER | June 2021 | October 2024 | Allow | 41 | 1 | 0 | No | No |
| 17328628 | DEVICES AND METHODS FOR FORMING AN ANASTOMOSIS | May 2021 | September 2024 | Allow | 39 | 1 | 0 | No | No |
| 17326974 | INTRAOCULAR DRAINAGE DEVICE | May 2021 | June 2025 | Allow | 49 | 1 | 1 | Yes | No |
| 17246620 | Liquid Dosing Medication Dispenser | May 2021 | February 2025 | Allow | 45 | 2 | 0 | No | No |
| 17245262 | AORTIC CANNULA FOR EX VIVO ORGAN CARE SYSTEM | April 2021 | August 2024 | Allow | 40 | 1 | 0 | No | No |
| 17228990 | PRESSURE-REGULATING VIAL ADAPTORS | April 2021 | April 2025 | Allow | 48 | 1 | 0 | No | No |
| 17206665 | SYSTEMS AND METHODS FOR TREATING A CAROTID ARTERY | March 2021 | August 2024 | Allow | 41 | 1 | 0 | Yes | No |
| 17192612 | TEMPORARY INTERATRIAL SHUNTS | March 2021 | September 2024 | Allow | 42 | 1 | 0 | No | No |
| 17176013 | PROCESSING BLOOD | February 2021 | June 2025 | Allow | 52 | 1 | 1 | No | No |
| 17175549 | SHUNT FOR REDISTRIBUTING ATRIAL BLOOD VOLUME | February 2021 | June 2025 | Allow | 52 | 1 | 1 | Yes | No |
| 17164122 | METHODS AND DEVICES FOR INCREASING AQUEOUS DRAINAGE OF THE EYE | February 2021 | April 2022 | Allow | 14 | 2 | 0 | Yes | No |
| 17150275 | MEMBRANE CATHETER | January 2021 | April 2025 | Abandon | 51 | 0 | 1 | No | No |
| 17147051 | Methods and Systems for Treating Intracranial Hypertension and Related Indications Using An Optic Nerve Stent or Shunt | January 2021 | November 2024 | Abandon | 46 | 1 | 0 | No | No |
| 17133000 | IMPLANTABLE FLOW CONNECTOR | December 2020 | November 2024 | Allow | 46 | 1 | 0 | No | No |
| 17107892 | CLOSED LOOP DIALYSIS TREATMENT USING ADAPTIVE ULTRAFILTRATION RATES | November 2020 | January 2025 | Allow | 49 | 1 | 0 | No | No |
| 16953558 | SYSTEMS AND METHODS FOR TREATING BLOOD | November 2020 | December 2024 | Allow | 49 | 2 | 0 | Yes | No |
| 16952565 | INTRAVENOUS INFUSION DOSAGE FORM | November 2020 | May 2025 | Allow | 53 | 1 | 1 | No | No |
| 17092610 | EXTERNALLY PROGRAMABLE MAGNETIC VALVE ASSEMBLY AND CONTROLLER | November 2020 | June 2025 | Allow | 56 | 2 | 1 | Yes | No |
| 17089150 | UVEOSCLERAL SHUNT AND METHODS FOR IMPLANTING SAME | November 2020 | August 2024 | Allow | 46 | 1 | 0 | No | No |
| 17071143 | URETERAL STENT WITH ANTI-MIGRATION FEATURES | October 2020 | March 2025 | Allow | 53 | 2 | 1 | Yes | No |
| 17065300 | APPARATUS FOR PERFORMING AN EXTRACORPOREAL BLOOD TREATMENT | October 2020 | June 2024 | Allow | 44 | 1 | 0 | No | No |
| 17062815 | SHUNT FLUSHERS AND RELATED METHODS | October 2020 | October 2024 | Abandon | 48 | 1 | 0 | No | No |
| 17061372 | DRUG ELUTING OCULAR IMPLANT | October 2020 | June 2025 | Allow | 56 | 1 | 1 | No | No |
| 17032070 | BLOOD TREATMENT DEVICE WITH AUTOMATIC AIR REMOVAL | September 2020 | October 2024 | Allow | 48 | 1 | 0 | No | No |
| 17040936 | HOLLOW FIBER MEMBRANE-TYPE ARTIFICIAL LUNG | September 2020 | January 2024 | Allow | 40 | 2 | 0 | No | No |
| 17026555 | CEREBROSPINAL FLUID DIVERSION FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME AND FIBROMYALGIA AND USE OF RNFL THINNING AS A BIOMARKER THEREFOR | September 2020 | July 2024 | Allow | 46 | 1 | 0 | No | No |
| 16980883 | Multi-Purpose Cap For Fluid Ports On A Medical Device | September 2020 | January 2021 | Allow | 4 | 1 | 0 | No | No |
| 16998606 | METHODS AND SYSTEMS FOR DRAINING CEREBROSPINAL FLUID INTO THE VENOUS SYSTEM | August 2020 | February 2024 | Allow | 42 | 1 | 0 | No | No |
| 16988998 | Magnetically Activated Arteriovenous Access Valve System and Related Methods | August 2020 | September 2024 | Allow | 49 | 1 | 0 | Yes | No |
| 16986245 | SYSTEMS AND METHODS FOR ENDOVASCULARLY ACCESSING A SUBARACHNOID SPACE | August 2020 | February 2024 | Allow | 42 | 1 | 0 | No | No |
| 16983110 | Devices and Methods for Extracorporeal Conditioning of Blood | August 2020 | March 2025 | Allow | 56 | 1 | 1 | Yes | No |
| 16966639 | DEVICE FOR REMOVING BY SUCTION A BODILY FLUID, PRIMARILY NASAL FLUID | July 2020 | September 2022 | Abandon | 25 | 2 | 0 | No | No |
| 16932623 | PRESERVATIVE REMOVAL FROM EYE DROPS | July 2020 | March 2021 | Allow | 8 | 0 | 0 | Yes | No |
| 16918494 | DEVICES AND METHODS FOR ON-LINE WHOLE BLOOD TREATMENT | July 2020 | October 2024 | Abandon | 51 | 1 | 0 | No | No |
| 16916316 | GLAUCOMA TREATMENT DEVICES AND METHODS | June 2020 | July 2024 | Abandon | 48 | 1 | 0 | No | No |
| 16910867 | GLAUCOMA TREATMENT DEVICES AND METHODS | June 2020 | October 2024 | Abandon | 52 | 1 | 0 | No | No |
| 16894474 | METHODS AND SYSTEMS FOR ESTABLISHING RETROGRADE CAROTID ARTERIAL BLOOD FLOW | June 2020 | March 2024 | Allow | 46 | 1 | 0 | No | No |
| 16765618 | DIGITAL EXTERNAL VENTRICULAR DRAIN WITH INTEGRATED INTRACRANIAL PRESSURE MONITOR AND CEREBRAL SPINAL FLUID MONITOR/PRESSURE REGULATOR | May 2020 | June 2024 | Allow | 48 | 1 | 1 | No | No |
| 16876864 | BLOOD TREATMENT AIR PURGING SYSTEM AND METHOD | May 2020 | February 2024 | Allow | 45 | 1 | 0 | No | No |
| 16875889 | BLOOD GAS EXCHANGER WITH RESTRICTION ELEMENT OR ELEMENTS TO REDUCE GAS EXCHANGE | May 2020 | March 2024 | Allow | 46 | 1 | 0 | Yes | No |
| 16868498 | INTRAOCULAR DRUG DELIVERY | May 2020 | November 2024 | Abandon | 55 | 1 | 0 | No | No |
| 16868253 | DELIVERY SYSTEM AND METHOD OF USE FOR THE EYE | May 2020 | May 2024 | Abandon | 49 | 1 | 0 | No | No |
| 16867047 | SYSTEM AND METHOD FOR TREATMENT OF PULMONARY EDEMA | May 2020 | December 2020 | Allow | 8 | 1 | 0 | No | No |
| 16866350 | Implantable Intracranial Pulse Pressure Modulator and System and Method for Use of Same | May 2020 | April 2021 | Allow | 12 | 1 | 0 | No | No |
| 16859955 | SUSTAINED RELEASE DELIVERY OF ACTIVE AGENTS TO TREAT GLAUCOMA AND OCULAR HYPERTENSION | April 2020 | May 2023 | Allow | 37 | 1 | 0 | No | No |
| 16849456 | APPARATUS FOR EXTRACORPOREAL BLOOD TREATMENT | April 2020 | October 2023 | Allow | 42 | 0 | 0 | Yes | No |
| 16844602 | SYSTEM AND METHOD FOR TREATING PULMONARY EDEMA | April 2020 | August 2021 | Allow | 16 | 3 | 0 | No | No |
| 16844592 | SYSTEM AND METHOD FOR TREATING PULMONARY EDEMA | April 2020 | August 2021 | Allow | 16 | 3 | 0 | No | No |
| 16830770 | CONTACTLESS ACTUATION FOR VALVE IMPLANT | March 2020 | June 2024 | Allow | 51 | 1 | 1 | No | No |
| 16824823 | DEVICES AND METHODS FOR ALLEVIATING LYMPHATIC SYSTEM CONGESTION | March 2020 | April 2025 | Allow | 60 | 2 | 1 | No | No |
| 16820153 | Resource-Generating Dialysis System | March 2020 | March 2023 | Allow | 36 | 1 | 1 | No | No |
| 16814522 | SYSTEM AND METHOD FOR TREATMENT OF PULMONARY EDEMA | March 2020 | October 2023 | Allow | 43 | 2 | 0 | No | No |
| 16810456 | VA ECMO with Pulmonary Artery Ventilation | March 2020 | February 2025 | Allow | 59 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WIEST, PHILIP R.
With a 20.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 25.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner WIEST, PHILIP R works in Art Unit 3781 and has examined 452 patent applications in our dataset. With an allowance rate of 90.3%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 34 months.
Examiner WIEST, PHILIP R's allowance rate of 90.3% places them in the 71% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by WIEST, PHILIP R receive 1.29 office actions before reaching final disposition. This places the examiner in the 24% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by WIEST, PHILIP R is 34 months. This places the examiner in the 25% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +6.5% benefit to allowance rate for applications examined by WIEST, PHILIP R. This interview benefit is in the 34% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 38.6% of applications are subsequently allowed. This success rate is in the 86% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 41.2% of cases where such amendments are filed. This entry rate is in the 56% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 36% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 64.3% of appeals filed. This is in the 39% percentile among all examiners. Of these withdrawals, 55.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 29.8% are granted (fully or in part). This grant rate is in the 22% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.9% of allowed cases (in the 67% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 42% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.